Shankar Hariharan
Founder, Co-CEO & Executive ChairmanDr. Shankar Hariharan, Ph.D., founded and served as President, Chief Executive Officer and Director of TRxADE HEALTH, Inc. (formerly known as Scienture Inc.). He is Founder and serves as Director of Scienture Holdings, Inc since July 25, 2024 and serves as its Co-CEO and Executive Chairman since May 20, 2025 and was its Chief Executive Officer until May 20, 2025. He serves as Director and as CEO of Scienture, LLC. He is senior Pharmaceutical R & D leader with experience in leading branded, specialty and generic pharmaceutical businesses. He is Member of Advisory Board of New Rhein Healthcare Investors LLC. He had managed all aspects of the Global Scientific Affairs function - PR&D, Global RA, clinical (NDAs, ANDAs and biosimilars), PV/safety, Labelling, Project and Portfolio Mgmt across multiple R & D centers. He served as an Executive Vice President and Chief Scientific Officer of Amneal Pharmaceuticals Inc. until April 2, 2019. Dr. Hariharan serves as Advisor of Scientific Strategy at Amneal Enterprises, LLC. Dr. Hariharan served as Vice President and Executive Vice President of Specialty Pharmaceuticals, Global R&D at Amneal Pharmaceuticals, L.L.C. Dr. Hariharan served as Chief Scientific Officer and Executive Vice President of Par Pharmaceutical Companies Inc., from June 2004 to November 15, 2006. Dr. Hariharan served as Vice President of Par Pharmaceutical Companies Inc. since July 2004. From 1990 to June 2004, he served in various positions, most served as Vice President for Pharmaceutical Research and Development and Senior Vice President of Forest Laboratories, Inc. He and his team made substantial contributions to the successful development of several important new products across various therapeutic areas, including the antidepressants Celexa(TM) and Lexapro(TM) and the Alzheimer's treatment, Namenda(TM). He joined Forest in 1990, accepting an assignment to manage Bioanalytical research and development. He later progressed through a series of positions of increasing responsibility, including vice president, pharmaceutical research and development (PRD). He managed PRD through a period of rapid change and expansion. Prior to joining Forest, he trained and managed a staff of research chemists at IDR Laboratory & Clinic, Ltd. in Rockville, Maryland. He joined IDR in 1987. He serves as a member of various scientific societies, including the American Association of Pharmaceutical Scientists. He served as a Member of Scientific Advisory Board of Optimer Pharmaceuticals, Inc. since June 2005. He has presented at several society and association meetings and has published various articles. He serves as Director of DepYmed, Inc. He is co-inventor of the method for the preparation of escitalopram. In 2003, Crain's New York Business named him to its list of 100 Most Powerful Minority Business Leaders in New York City. He completed his bachelor's degree in pharmacy at Banaras Hindu University in India and his Ph.D. in Pharmaceutical Sciences from Northeastern University in Boston, Massachusetts. Dr. Hariharan holds Masters degrees in Pharmacy.
Positions
- Company NameScienture Holdings, Inc.Stock CodeSCNXPositionFounder, Co-CEO & Executive ChairmanColleagues
- NMNarasimhan ManiPresident, Co-CEO, Interim CFO & Director
- RSRahul SuranaExecutive VP & COO of Scienture LLC
- MRMichele RathSenior VP & Chief Commercial Officer of Scienture LLC
- DGDonald G. FellIndependent Director
- MMMayur Mansukhlal DoshiIndependent Director
- SKSuneel K. GuptaMember of Scientific Advisory Board
